Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Accuray ( (ARAY) ) has shared an announcement.
On February 5, 2025, Accuray announced strong financial results for the second quarter of fiscal 2025, ending December 31, 2024, with total net revenue increasing by 8% year-over-year to $116.2 million. The company reported a net income of $2.5 million, reversing a net loss from the previous year, and noted significant demand for its Tomo C System and Helix system, particularly in emerging markets. Accuray has raised its fiscal year 2025 guidance and credits its success to strategic execution and continued innovation in product offerings, aiming to enhance cancer care and expand market presence.
More about Accuray
Accuray Incorporated, headquartered in Madison, Wisconsin, specializes in developing innovative radiation therapy solutions for oncology and neuro-radiosurgery. The company focuses on creating market-changing technologies aimed at improving patient care and expanding the potential of radiation therapy across complex and commonly treatable cases.
YTD Price Performance: 19.49%
Average Trading Volume: 671,875
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $234.3M
For a thorough assessment of ARAY stock, go to TipRanks’ Stock Analysis page.
